Julie Curphey appointed following director of commercial operations role.
Helius Therapeutics has appointed Julie Curphey as Chief Commercial Officer following two months as director of commercial operations.
The company is New Zealand’s largest licenced medicinal cannabis business.
“Announcing Curphey as our CCO reaffirms that Helius has a globally experienced team that’s busy getting the job done,” Helius Therapeutics chief executive Carmen Doran said.
Before joining Helius, Curphey spent five years as chief marketing officer at Blis Technologies based in Dunedin.
For 11 years she was with Pfizer overseas, joining as group manager of business intelligence and market research at Pfizer Australia, before transferring to Pfizer UK as business intelligence team leader. She was appointed head of customer intelligence for Pfizer Europe’s primary care business unit, then European brand team leader for Viagra, and most recently, director of business operations/chief of staff.
Curphey said she is delighted to be part of New Zealand’s medicinal cannabis industry which in the past year has transitioned from an aspirational space to one of delivery.
“There is considerable unmet need out there and much work to do to make medicinal cannabis as accessible as possible,” she said.
Helius was New Zealand’s first medicinal cannabis business to achieve a GMP licence for manufacturing medicines in July 2021, covering the first products to market.
Last month, Helius was awarded the industry’s first licence renewal and expansion to enable it to produce both New Zealand grown and made CBD active ingredients and products.
This is supplied content and not commissioned or paid for by NBR.
